Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — H1 2017 Earnings Presentation
31 slides from Pt Prodia Widyahusada Tbk's earnings presentation, Jul 31, 2017
Slide 1: PT Prodia Widyahusada Tbk 1H 2017 Results Update
CONFIDENTIAL PT Prodia Widyahusada Tbk 1H 2017 RESULTS UPDATE 31 July 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Contents
confidential CONTENTS 1 INVESTMENT HIGHLIGHTS 2 1H 2017 BUSINESS UPDATE 3 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 3
Slide 4: Investment Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 1H 2017 BUSINESS UPDATE 3 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 4
Slide 5: Key Business Highlights
confidential Key Business Highlights
Slide 6: Prodia is at Forefront of Significant Indonesian Healthcare Opportunity
confidential 1. PRODIA is at Forefront of Significant Indonesian Healthcare Opportunity Total Indonesia Healthcare Expenditure Significant Long-term Growth Potential (In USD bn) A Population of 256 million – 4th Largest Worldwide (3) Rapidly expanding middle class 29.0 Strong GDP growth 27.6 2
Slide 7: Significant Growth Potential for Private Laboratories in Indonesia
1. Significant Growth Potential for Private Laboratories in confidential Indonesia Indonesian Healthcare Market is Growing Private Laboratory Testing Market is Growing Faster (Market size by revenue; In USD bn) (Market size by revenue; In USD mn) 13A-15E CAGR (0.3%) 817 29 28 27 27 26 706 25 24 615
Slide 8: Indonesian Pioneer in Clinical Laboratory Testing
2. Indonesian Pioneer in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS 2015, along with the Award as "Diagnostic Services Company of the Year 2015" from Frost & Sullivan Opened the first green building used for laboratories in Indonesia, Graha Prodia, in Surabaya Establishe
Slide 9: Largest Nationwide Network
confidential 3. Largest Nationwide Network I II VII Clinical Labs Clinical Specialty POC Hospital Clinical POC Clinical Specialty POC Hospital Labs Clinic Outlet Lab Labs Outlet And Labs Clinic Outlet Lab 131 1 PHC 15 0 5 1 7 0 6 1 7 2 and 1 & Upgrade PHC : 10 I Kalimantan VIII V II Sulawesi Clinica
Slide 10: Scalable Hub and Spoke Model
confidential 3. Scalable “Hub and Spoke” Model Prodia Clinical Labs, Hospital Centralized information and Other Clinics refer tests to Prodia National with integrated IT “Hub and spoke” model offers Reference Lab PNRL (PNRL) platform that connects scalable platform reducing each lab to PNRL tu
Slide 11: Most Recognized Clinical Lab Brand in Indonesia
confidential 4. Most recognized Clinical Lab Brand in Indonesia The only clinical lab in Indonesia accredited by College of American Pathologists Pioneer in Indonesian Laboratory Services (“CAP”(3)) Received 56% of the votes from a sample of Center of Excellence Indonesian consumers in the 2015
Slide 12: Comprehensive Service Offering – Target Multiple Customer Segments
confidential 5. Comprehensive Service Offering –Target Multiple Customer Segments
Slide 13: Prodia Most Recognized Clinical Lab Brand
confidential 5. PRODIA Most Recognized Clinical Lab brand Corporate Indonesia Indonesia Best Top Brand Award Image Award Original Brand Brand Award 2009 - 2016 (IMAC) (IOB ) 2012 - (IBBA) 2012 - 2016 2016 2013 - 2016 2016 Service Quality Award 2015 - 2016 2013, 2015 - 2016 Rekor Bisnis 2013 Satria B
Slide 14: Senior Leadership and Management Team
confidential 7.Senior Leadership and Management Team Diagnostic Services Best Brand Gold Company of the Year 2015 2015 - Frost & Sullivan - IBBA Awards Drs. Gunawan Dr. Endang Scott Andrew Joseph Dr. Andi Prawiro Soeharto Hoyaranda Merrillees F. P, Luhukay Wijaya, MBA Co-Founder and Co-Founder and C
Slide 15: Share Holder
SHARE HOLDER No.1 clinical lab chain in Indonesia(1) Premium clinical laboratory brand Dominant and industry pioneer PT. PRODIA WIDYAHUSADA TBK Nationwide Outlet Network across Indonesia PT. Prodia Utama Bio Majesty Pte. Ltd Public 57% 18% 25.0% 15 confidential
Slide 16: Pioneer and Leader in Indonesian Independent Clinical Lab Industry
Pioneer 2 and Pioneer Leader ininIndonesian and Leader Independent Indonesian Independent Clinical Lab Industry confidential Clinical Lab Industry No.1 Independent Clinical Lab Chain Largest and Most Diversified Laboratory Network Market Share by Revenue of Key Players (2015) Number of Labs of 6 Key
Slide 17: 1H 2017 Business Update
confidential 1 INVESTMENT HIGHLIGHTS 2 1H 2017 BUSINESS UPDATE 3 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 17
Slide 18: 2017 Network Developments
2017 Network Developments 1 Upgrade Reference Lab Clinical Lab to & Next Gen Specialty Clinic Hospital Clinical Lab Lab (Jakarta) POC Outlets Laboratories PHC 2 5-7 1 20 3-5 8-10 Expanding Service Network, Developing Personalized Medicine
Slide 19: 1H Revenue 2017
1H Revenue 2017 Revenue Growth (In IDR bn) 1,359 1,198 1,081 986 649 673 2013 2014 2015 2016 1H 2016 1H 2017 Revenue increased by 3.8% drive by external referral and corporate clients Walk in customer and Doctors Referral are two segments that impacted by Ramadhan season, Iedul Fitri festive hol
Slide 20: 1H 2017 New Testing Types
1H 2017 New TESTING TYPES Molecular Immunology Others • CT/NG RT PCR • Aldosteron • Fragmentation of • Warfarin Indiv Test DNA Sperm (CYP2C & VCORC1 genotype) • MTB/MOTT-DNA • Telomere • Mutation of JAK2 V617 Screening Package • Wellness Basic/Medium/Premium Package
Slide 21: 1H 2017 Prodia Recognition Award
confidential 1H 2017 PRODIA Recognition Award Corporate Indonesia Most Top Brand Award Image Award Wow Brand Award Creative Companies 2009 - 2017 (IMAC) 2015 & 2017 2017 2012 - 2017 Satria Brand Award Master Service Award 2011 - 2017 2015 - 2017 2012 - 2017
Slide 22: Technology to increase customer satisfaction
Technology to increase customer satisfaction Launched e-Pay and e-Reg to increase distribution channel and provide easier way to register and payment system Payment can be made through ATM Transfer and Credit Card Customers can access their laboratory results through PRODIA apps and email
Slide 23: H1 2017 Results
confidential H1 2017 Results Financial 1H 2016 1H 2017 Revenue (IDR Bn) 648.63 672.61 ▲ 3.70% EBITDA (IDR Bn) 100.43 92.21 ▼ 8.19% EBITDA Margin 15.5% 13.7% ▼ 180 bps Net Income (IDR Bn) 39.09 58.75 ▲ 50.28% Upgrade Clinical Lab to PHC 10 • No of visits (mn) POCs 10-2* • Revenue per visit (IDR 000)
Slide 24: Growth Strategies
confidential 1 INVESTMENT HIGHLIGHT 2 1H 2017 BUSINESS UPDATE 3 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHT 26
Slide 25: Growth Strategies
confidential Growth Strategy Growth Strategies A Near-term 1 Expand our presence and grow our network of outlets in both existing and new markets in Indonesia 2 Upgrade existing clinical laboratories to provide wider range of tests and services and increase volume 3 Enhance internal operating effici
Slide 26: Near Term Growth Plan
confidential NEAR Term Growth Plan Prodia’s Network Expansion Plan in Five Years 1 2 Expand Network of Outlets Upgrade Clinical Labs Upgrade up to 39 additional clinical labs to 4 regional reference labs(1) PHC Clinics(3) Up to 33 additional clinical labs over next five years 24 Clinical Lab Improve
Slide 27: Leader in Next Generation Technology
Leader in Next Generation Technology confidential (Long-term Strategy) Immunology Laboratory Platforms Molecular Diagnostics (Flow Cytometry) Lab Innovation Diversified Clinical Diagnostics Platform + Scientific Talent Chromatography-Mass Advanced Pathology Lab Spectrometry The Concept of Precision
Slide 28: Financial Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 1H 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 30
Slide 29: 1H 2017 Gross Profit and Net Income
confidential 1H 2017 Gross Profit and Net Income (unaudited Report) Gross Profit Net Income In IDR bn In IDR bn Net Income 59 39 57.9% 380 387 8.7% %6.8 58.5% 57.5% 1H 2016 1H 2017 1H 2016 1H 2017 Gross Profit slow down by 1% as volume testing drop by 4%. Net income increased by 50.28% as reduce
Slide 30: 1H 2017 Cost Structure
confidential 1H 2017 Cost Structure (unaudited Report) Cost of Revenues (In IDR bn) 42.7% 42.5% 42.0% 41.6% 565 41.5% 511 454 90 384 82 72 47 269 286 337 475 45 47 382 429 224 239 38.9% 2013A 2014A 2015A 2016 A H1 2016 A H1 2017 A Indirect Cost Direct Cost Cost of Revenues as % of Total Revenue Oper
Slide 31: Thank You
THANK YOU
PT Prodia Widyahusada — H1 2017 Earnings Presentation on 6ix